EPHA4 GENETIC VARIANT IN A PATIENT WITH EPILEPSY, OPHTHALMOLOGICAL ANOMALIES, AND NEURODEVELOPMENTAL DELAY
Sleptsova M, Georgiev C, Atemin S, Dimova P, Avdjieva-Tzavella D, Tacheva G, Litvinenko I, Grozdanova L, Todorov T, Mitev V, Todorova A
*Corresponding Author: Mila Sleptsova, BSc, Genetic Medico-Diagnostic Laboratory “Genica”, 84 Ami Bue Street, Sofia, Bulgaria; Email: milasleptsova99@gmail.com
page: 65
|
|
REFERENCES
1. Helbig, I. and Abou Tayoun, A. N. (2016) ‘Under-
standing Genotypes and Phenotypes in Epileptic En-
cephalopathies’, Molecular Syndromology, 7(4), pp.
172–181.
2. Light, T. P., Gomez-Soler, M., Wang, Z., Karl, K.,
Zapata-Mercado, E., Gehring, M. P., Lechtenberg,
B. C., Pogorelov, T. V., Hristova, K. and Pasquale,
E. B. (2021) ‘A cancer mutation promotes EphA4
oligomerization and signaling by altering the confor-
mation of the SAM domain’, Journal of Biological
Chemistry, 297(1), p. 100876.
3. National Center for Biotechnology Information. Clin-
Var (no date) [VCV000431727.1].
4. Van Hoecke, A., Schoonaert, L., Lemmens, R., Tim-
mers, M., Staats, K. A., Laird, A. S., Peeters, E., Phil-
ips, T., Goris, A., Dubois, B., et al. (2012) ‘EPHA4
is a disease modifier of amyotrophic lateral sclerosis
in animal models and in humans’, Nature Medicine,
18(9), pp. 1418–1422.
5. Fu, A. K. Y., Hung, K.-W., Huang, H., Gu, S., Shen,
Y., Cheng, E. Y. L., Ip, F. C. F., Huang, X., Fu, W.-Y.
and Ip, N. Y. (2014) ‘Blockade of EphA4 signaling
ameliorates hippocampal synaptic dysfunctions in
mouse models of Alzheimer’s disease’, Proceedings
of the National Academy of Sciences, 111(27), pp.
9959–9964.
6. Goldshmit, Y. and Bourne, J. (2010) ‘Upregulation of
EphA4 on Astrocytes Potentially Mediates Astrocytic
Gliosis after Cortical Lesion in the Marmoset Mon-
key’, Journal of Neurotrauma, 27(7), pp. 1321–1332.
7. Miller, S. A., Dykes, D. D. and Polesky, H. F. (1988)
‘A simple salting out procedure for extracting DNA
from human nucleated cells’, Nucleic Acids Research,
16(3), pp. 1215–1215.
8. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S.,
Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon,
E., Spector, E., et al. (2015) ‘Standards and guidelines
for the interpretation of sequence variants: a joint
consensus recommendation of the American College
of Medical Genetics and Genomics and the Associa-
tion for Molecular Pathology’, Genetics in Medicine,
17(5), pp. 405–424.
9. Wiel, L., Baakman, C., Gilissen, D., Veltman, J.
A., Vriend, G. and Gilissen, C. (2019) ‘MetaDome:
Pathogenicity analysis of genetic variants through
aggregation of homologous human protein domains’,
Human Mutation, p. humu.23798.
10. Paysan-Lafosse, T., Blum, M., Chuguransky, S.,
Grego, T., Pinto, B. L., Salazar, G. A., Bileschi, M.
L., Bork, P., Bridge, A., Colwell, L., et al. (2023)
‘InterPro in 2022’, Nucleic Acids Research, 51(D1),
pp. D418–D427.
11. Fuller, Z. L., Berg, J. J., Mostafavi, H., Sella, G. and
Przeworski, M. (2019) ‘Measuring intolerance to mu-
tation in human genetics’, Nature Genetics, 51(5), pp.
772–776.
12. Karczewski, K. J., Francioli, L. C., Tiao, G., Cum-
mings, B. B., Alföldi, J., Wang, Q., Collins, R. L.,
Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al.
(2020) ‘The mutational constraint spectrum quan-
tified from variation in 141,456 humans’, Nature,
581(7809), pp. 434–443.
13. Nagy, E. and Maquat, L. E. (1998) ‘A rule for termi-
nation-codon position within intron-containing genes:
when nonsense affects RNA abundance’, Trends in
Biochemical Sciences, 23(6), pp. 198–199.
14. Arvanitis, D. N. and Davy, A. (2012) ‘Regulation
and misregulation of Eph/ephrin expression’, Cell
Adhesion & Migration, 6(2), pp. 131–137.
15. Sobreira, N., Schiettecatte, F., Valle, D. and Hamosh,
A. (2015) ‘GeneMatcher: A Matching Tool for Con-
necting Investigators with an Interest in the Same
Gene’, Human Mutation, 36(10), pp. 928–930.
16. Oliver, K. L., Scheffer, I. E., Bennett, M. F., Grinton,
B. E., Bahlo, M. and Berkovic, S. F. (2023) ‘Gen-
es4Epilepsy: An epilepsy gene resource’, Epilepsia,
64(5), pp. 1368-1375.
|
|
|
